Uy Ear
Stock Analyst at Mizuho Securities
(4.06)
# 1,719
Out of 5,189 analysts
616
Total ratings
43.3%
Success rate
6.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals | Rated: Hold | n/a | $17.11 | - | 41 | Sep 15, 2026 | |
| ARQT Arcutis Biotherapeutics | Rated: Hold | n/a | $26.36 | - | 165 | Sep 15, 2026 | |
| EOLS Evolus | Rated: Hold | n/a | $6.52 | - | 53 | Sep 15, 2026 | |
| INAB IN8bio | Rated: Hold | n/a | $0.758 | - | 18 | Sep 15, 2026 | |
| MBX MBX Biosciences | Rated: Hold | n/a | $49.55 | - | 14 | Sep 15, 2026 | |
| QTTB Q32 Bio | Rated: Hold | n/a | $8.34 | - | 1 | Sep 15, 2026 | |
| QURE uniQure | Rated: Hold | n/a | $19.35 | - | 28 | Sep 15, 2026 | |
| RLMD Relmada Therapeutics | Rated: Hold | n/a | $2.62 | - | 39 | Sep 15, 2026 | |
| RNAC Cartesian Therapeutics | Rated: Hold | n/a | $6.14 | - | 30 | Sep 15, 2026 | |
| SLGL Sol-Gel Technologies | Rated: Hold | n/a | $55.17 | - | 3 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.33 | - | 65 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $20.73 | - | 36 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $44.94 | +44.64% | 62 | Sep 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $146 → $175 | $150.57 | +16.23% | 38 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.7679 | n/a | 13 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.9361 | n/a | 9 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $14 | $4.70 | n/a | 1 | Jul 10, 2019 |
Acadia Pharmaceuticals
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $17.11
Upside: -
Arcutis Biotherapeutics
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $26.36
Upside: -
Evolus
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $6.52
Upside: -
IN8bio
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $0.758
Upside: -
MBX Biosciences
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $49.55
Upside: -
Q32 Bio
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $8.34
Upside: -
uniQure
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $19.35
Upside: -
Relmada Therapeutics
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $2.62
Upside: -
Cartesian Therapeutics
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $6.14
Upside: -
Sol-Gel Technologies
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $55.17
Upside: -
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $13.33
Upside: -
Sep 15, 2026
Rated: Hold
Price Target: n/a
Current: $20.73
Upside: -
Sep 4, 2026
Reiterated: Buy
Price Target: $65
Current: $44.94
Upside: +44.64%
Dec 12, 2025
Reiterated: Hold
Price Target: $146 → $175
Current: $150.57
Upside: +16.23%
Aug 18, 2023
Rated: Hold
Price Target: n/a
Current: $0.7679
Upside: n/a
Aug 11, 2023
Rated: Hold
Price Target: n/a
Current: $0.9361
Upside: n/a
Jul 10, 2019
Initiated Coverage: Hold
Price Target: $14
Current: $4.70
Upside: n/a